The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Abstract
CONTEXT: Neurocognitive impairment in schizophrenia is severe and is an important predictor of functional outcome. The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined. OBJECTIVE: To compare the neurocognitive effects of several second-generation antipsychotics and a first-generation antipsychotic, perphenazine. DESIGN: Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al. Ziprasidone hydrochloride was included after its approval by the Food and Drug Administration. SETTING: Fifty-seven sites participated, including academic sites and treatment mental health facilities representative of the community. PATIENTS: From a cohort of 1460 patients in the treatment study, 817 completed neurocognitive testing immediately prior to randomization and then after 2 months of treatment. MAIN OUTCOME MEASURES: The primary outcome was change in a neurocognitive composite score after 2 months of treatment. Secondary outcomes included neurocognitive composite score change at 6 months and 18 months after continued treatment and changes in neurocognitive domains. RESULTS: At 2 months, treatment resulted in small neurocognitive improvements of z = 0.13 for olanzapine (P<.002), 0.25 for perphenazine (P<.001), 0.18 for quetiapine (P<.001), 0.26 for risperidone (P<.001), and 0.12 for ziprasidone (P<.06), with no significant differences between groups. Results at 6 months were similar. After 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups. Neurocognitive improvement predicted longer time to treatment discontinuation, independently from symptom improvement, in patients treated with quetiapine or ziprasidone. CONCLUSIONS: After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition. There were no differences between any pair of agents, including the typical drug perphenazine. These results differ from the majority of previous studies, and the possible reasons are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Wechsler Intelligence Scale for Children
(2018) · The SAGE Encyclopedia of Intellectual and Developmental Disorders · doi:10.4135/9781483392271.n537 · Cited by 4,109
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Self-citationNeurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Wide Range Achievement Test-Revised
McCloskey, G. (1987) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine) · Cited by 1,375
The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry
Robbins, T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1154-7 · Cited by 1,282
Neuropsychological Function in Schizophrenia: Selective Impairment in Memory and Learning
Saykin, A. J. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810310036007 · Cited by 1,155
Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
Saykin, A. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020048005 · Cited by 1,086
Cited by
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
The Diagnosis of Mental Disorders: The Problem of Reification
Hyman, S. E. (2010) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.3.022806.091532 · Cited by 1,052
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,027
Schizophrenia Is a Cognitive Illness: Time for a Change in Focus
Kahn, R. S., & Keefe, R. S. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.155 · Cited by 825
Self-citationAnimal models of schizophrenia
Jones, C., Watson, D., & Fone, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01386.x · Cited by 771
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 741
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Reinforcement Learning in Healthcare: A Survey
Yu, C., Liu, J., Nemati, S., & Yin, G. (2023) · ACM Computing Surveys · doi:10.1145/3477600 · Cited by 628
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Dendritic spine pathology in schizophrenia
Glausier, J. R., & Lewis, D. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.04.044 · Cited by 581
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Schizophrenia: overview and treatment options.
(2014) · PubMed Central · Cited by 533
Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
A Possible Role for the Striatum in the Pathogenesis of the Cognitive Symptoms of Schizophrenia
Simpson, E. H., Kellendonk, C., & Kandel, E. (2010) · Neuron · doi:10.1016/j.neuron.2010.02.014 · Cited by 478
Cognitive Impairment in Schizophrenia
Keefe, R. S. E., & Harvey, P. D. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_2 · Cited by 472
Self-citationCognitive Deficits in Psychotic Disorders: A Lifespan Perspective
Sheffield, J. M., Karcher, N. R., & Barch, D. M. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9388-2 · Cited by 457
Update on Typical and Atypical Antipsychotic Drugs
Meltzer, H. Y. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050911-161504 · Cited by 433
Using Neuroplasticity-Based Auditory Training to Improve Verbal Memory in Schizophrenia
Fisher, M., Holland, C., Merzenich, M. M., & Vinogradov, S. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08050757 · Cited by 426
Schizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 409
Goldberg, T. E., Goldman, R. S., Burdick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C., Woerner, M. G., Schooler, N. R., Kane, J. M., & Robinson, D. G. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1115 · Cited by 394
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
The role of serotonin receptors in the action of atypical antipsychotic drugs
Meltzer, H., & Massey, B. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.007 · Cited by 381
Eack, S. M., Hogarty, G. E., Cho, R. Y., Prasad, K. M. R., Greenwald, D. P., Hogarty, S. S., & Keshavan, M. S. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.63 · Cited by 360
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Goldberg, T. E., Harvey, P. D., Wesnes, K. A., Snyder, P. J., & Schneider, L. S. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.003 · Cited by 343
Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder
Lewandowski, K. E., Cohen, B. M., & Öngur, D. (2011) · Psychological Medicine · doi:10.1017/s0033291710001042 · Cited by 336
Zhang, J.-P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 336
The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China
Shi, C., Kang, L., Yao, S., Ma, Y., Li, T., Liang, Y., Cheng, Z., Xu, Y., Shi, J., Xu, X., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.09.003 · Cited by 324
Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, R. S., Boter, H., Keet, I. P. M., Prelipceanu, D., Rybakowski, J. K., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08060806 · Cited by 320
Self-citationWhat Do We Know About Neuropsychological Aspects Of Schizophrenia?
Palmer, B. W., Dawes, S. E., & Heaton, R. K. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9109-y · Cited by 316
Simonsen, C., Sundet, K., Vaskinn, A., Birkenaes, A. B., Engh, J. A., Faerden, A., Jonsdottir, H., Ringen, P. A., Opjordsmoen, S., Melle, I., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp034 · Cited by 310
Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M., & Geyer, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.004 · Cited by 298
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Koblan, K. S., Kent, J., Hopkins, S. C., Krystal, J. H., Cheng, H., Goldman, R., & Loebel, A. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911772 · Cited by 297
Swartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., Reimherr, F., McGee, M. F., Keefe, R. S. E., McEvoy, J. P., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.428 · Cited by 291
Self-citationFunctional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Snyder, G. L., Vanover, K. E., Zhu, H., Miller, D. B., O’Callaghan, J. P., Tomesch, J., Li, P., Zhang, Q., Krishnan, V., Hendrick, J. P., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3704-1 · Cited by 289
Schmidt, C. J., Chapin, D. S., Cianfrogna, J., Corman, M. L., Hajos, M., Harms, J. F., Hoffman, W. E., Lebel, L. A., McCarthy, S. A., Nelson, F. R., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132910 · Cited by 284
Vigen, C. L. P., Mack, W. J., Keefe, R. S. E., Sano, M., Sultzer, D. L., Stroup, T. S., Dagerman, K. S., Hsiao, J. K., Lebowitz, B. D., Lyketsos, C. G., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.08121844 · Cited by 281
Self-citationKeefe, R. S. E., Sweeney, J. A., Gu, H., Hamer, R. M., Perkins, D. O., McEvoy, J. P., & Lieberman, J. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1061 · Cited by 276
Self-citationTandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, J. J., Okasha, A., Singh, B., Stein, D. J., Olie, J.-P., Fleischhacker, W. W., & Moeller, H.-J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.033 · Cited by 276
Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia
Fatouros-Bergman, H., Cervenka, S., Flyckt, L., Edman, G., & Farde, L. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.034 · Cited by 273
Nielsen, R. E., Levander, S., Kjaersdam Telléus, G., Jensen, S. O. W., Østergaard Christensen, T., & Leucht, S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12374 · Cited by 270
Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.050088 · Cited by 265
Self-citationQuetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., & Lieberman, J. A. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn067 · Cited by 258
Self-citationCarbon, M., & Correll, C. U. (2014) · CNS Spectrums · doi:10.1017/s1092852914000601 · Cited by 258
Cognition in schizophrenia: Past, present, and future
Green, M. F., & Harvey, P. D. (2014) · Schizophrenia Research: Cognition · doi:10.1016/j.scog.2014.02.001 · Cited by 258
Treating Working Memory Deficits in Schizophrenia: A Review of the Neurobiology
Lett, T. A., Voineskos, A. N., Kennedy, J. L., Levine, B., & Daskalakis, Z. J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.026 · Cited by 257
Kimhy, D., Vakhrusheva, J., Bartels, M. N., Armstrong, H. F., Ballon, J. S., Khan, S., Chang, R. W., Hansen, M. C., Ayanruoh, L., Lister, A., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv022 · Cited by 207
Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193
Self-citationBuchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., Gold, J. M., Green, M. F., Jarskog, L. F., Javitt, D. C., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.052 · Cited by 172
Self-citationGalantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170
Buchanan, R. W., Keefe, R. S. E., Umbricht, D., Green, M. F., Laughren, T., & Marder, S. R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq038 · Cited by 154
Self-citationCognitive impairments in psychotic disorders: common mechanisms and measurement
Barch, D. M., & Sheffield, J. M. (2014) · World Psychiatry · doi:10.1002/wps.20145 · Cited by 154
Watson, D. J., Loiseau, F., Ingallinesi, M., Millan, M. J., Marsden, C. A., & Fone, K. C. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.254 · Cited by 151
Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview
Dias, V. V., Balanzá‐Martinez, V., Soeiro‐de‐Souza, M. G., Moreno, R. A., Figueira, M. L., Machado‐Vieira, R., & Vieta, E. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01910.x · Cited by 146
Jeppesen, R., Christensen, R. H. B., Pedersen, E. M. J., Nordentoft, M., Hjorthøj, C., Köhler-Forsberg, O., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.08.028 · Cited by 132
Achim, A. M., Ouellet, R., Roy, M.-A., & Jackson, P. L. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2010.10.030 · Cited by 128
Rodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301654 · Cited by 126
McClay, J. L., Adkins, D. E., Åberg, K., Bukszár, J., Khachane, A. N., Keefe, R. S. E., Perkins, D. O., McEvoy, J. P., Stroup, T. S., Vann, R. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.193 · Cited by 124
Self-citationCognition as a target in schizophrenia, bipolar disorder and depression
Martinez-Aran, A., & Vieta, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.007 · Cited by 101
Quan, M., Lee, S.-H., Kubicki, M., Kikinis, Z., Rathi, Y., Seidman, L. J., Mesholam-Gately, R. I., Goldstein, J. M., McCarley, R. W., Shenton, M. E., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2012.11.028 · Cited by 97
Schmidt, A., Smieskova, R., Aston, J., Simon, A., Allen, P., Fusar-Poli, P., McGuire, P. K., Riecher-Rössler, A., Stephan, K. E., & Borgwardt, S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.117 · Cited by 93
The muscarinic system, cognition and schizophrenia
Carruthers, S. P., Gurvich, C. T., & Rossell, S. L. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.011 · Cited by 90
Hutcheson, N. L., Sreenivasan, K. R., Deshpande, G., Reid, M. A., Hadley, J., White, D. M., Ver Hoef, L., & Lahti, A. C. (2015) · Human Brain Mapping · doi:10.1002/hbm.22714 · Cited by 79
Idris, N., Neill, J., Grayson, B., Bang-Andersen, B., Witten, L. M., Brennum, L. T., & Arnt, J. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1702-5 · Cited by 74
Substance use and schizophrenia: adverse correlates in the CATIE study sample
Kerfoot, K. E., Rosenheck, R. A., Petrakis, I. L., Swartz, M. S., Keefe, R. S. E., McEvoy, J. P., & Stroup, T. S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.032 · Cited by 70
Self-citationOrlov, N. D., Tracy, D. K., Joyce, D., Patel, S., Rodzinka-Pasko, J., Dolan, H., Hodsoll, J., Collier, T., Rothwell, J., & Shergill, S. S. (2017) · Brain Stimulation · doi:10.1016/j.brs.2016.12.013 · Cited by 69
Cognitive markers of psychotic unipolar depression: A meta-analytic study
Zaninotto, L., Guglielmo, R., Calati, R., Ioime, L., Camardese, G., Janiri, L., Bria, P., & Serretti, A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.027 · Cited by 61
Broader visual orientation tuning in patients with schizophrenia
Rokem, A., Yoon, J. H., Ooms, R. E., Maddock, R. J., Minzenberg, M. J., & Silver, M. A. (2011) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2011.00127 · Cited by 50
Cognitive Remediation in Schizophrenia
Kaneko, Y., & Keshavan, M. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.3.125 · Cited by 51
Janhunen, S. K., Svärd, H., Talpos, J., Kumar, G., Steckler, T., Plath, N., Lerdrup, L., Ruby, T., Haman, M., Wyler, R., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3954-6 · Cited by 43
“On the other hand, the fact that antipsychotics improve cognitive performance in schizophrenia only at low doses and modestly, if any (Keefe et al. 2007), raises a concern for the predictive validity of the scPCP-impaired NOR test.”
BackgroundInfluentialCognition in at-risk mental states for psychosis
de Paula, A. L. D., Hallak, J. E. C., Maia-de-Oliveira, J. P., Bressan, R. A., & Machado-de-Sousa, J. P. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.006 · Cited by 43
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Chesney, E., Oliver, D., & McGuire, P. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05905-9 · Cited by 40
Eack, S. M., Newhill, C. E., & Keshavan, M. S. (2016) · Journal of the Society for Social Work and Research · doi:10.1086/686538 · Cited by 37
Cadena, E. J., White, D. M., Kraguljac, N. V., Reid, M. A., & Lahti, A. C. (2018) · npj Schizophrenia · doi:10.1038/s41537-018-0051-y · Cited by 36
Prefrontal cortical GABAergic and NMDA glutamatergic regulation of delayed responding
Auger, M. L., & Floresco, S. B. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.022 · Cited by 28
Acheson, D. T., Twamley, E. W., & Young, J. W. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00103 · Cited by 26
Koychev, I., Barkus, E., Ettinger, U., Killcross, S., Roiser, J. P., Wilkinson, L., & Deakin, B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111414450 · Cited by 24
Carli, M., Calcagno, E., Mainini, E., Arnt, J., & Invernizzi, R. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2066-6 · Cited by 20
Hurtado, M. M., Triviño, M., Arnedo, M., Roldán, G., & Tudela, P. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.09.027 · Cited by 19
“…symptomatology interferes with cognitive processing, including executive functions (Farrin et al., 2003; Landrø et al., 2001; Saykin et al., 1991), but both antidepressants and antipsychotic drugs improve neurocognition in these clinical populations (Keefe et al., 2007; Gualtieri et al., 2006).”
Ding, Y., Hou, W., Wang, C., Sha, S., Dong, F., Li, X., Wang, N., Lam, S. T., Zhou, F., & Wang, C. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.06.048 · Cited by 9
Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4
Addressing altered anticipation as a transdiagnostic target through computational psychiatry
Sepúlveda, P., Aitsahalia, I., Kumar, K., Atkin, T., & Iigaya, K. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.02.014 · Cited by 3
Neural correlates of set-shifting: decomposing executive functions in schizophrenia
Wilmsmeier, A., Ohrmann, P., Suslow, T., Siegmund, A., Koelkebeck, K., Rothermundt, M., Kugel, H., Arolt, V., Bauer, J., & Pedersen, A. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.090181 · Cited by 63
Metadata
- Authors
- Keefe, R. S. E.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2007-06-01
- Volume
- 64
- Issue
- 6
- Pages
- 633
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2170792659
- Cited by
- 1,065
- References
- 83
- FWCI
- 45.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.